HLB Therapeutics Co.,Ltd.
115450
Clasificación en acciones
#18158
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Precio por acción
$2.08
Capitalización bursátil
$195.98M
Cambio (1 día)
10.97%
Cambio (1 año)
1.60%
País
KR
Comercio HLB Therapeutics Co.,Ltd. (115450)
Categoría
Healthcare
Ratio P/B de HLB Therapeutics Co.,Ltd. (115450)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de HLB Therapeutics Co.,Ltd., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de HLB Therapeutics Co.,Ltd. desde 2026 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| 6.1824 | - |
NL
|
|
| - | - |
CH
|
